Jiangsu AmbioPharm Biopharmaceutical Co., Ltd.

Nortex Biotech (stock code 688076) focuses on polypeptide drugs and small molecule drugs, adopts the combination of independent R&D and custom R&D and production, and forms self-developed and customized two-wheel drive in the fields of advanced pharmaceutical intermediates, APIs and preparations. The company was established in Lianyungang in 2009 and listed on the Science and Technology Innovation Board in 2021. Its Hangzhou Aosino focuses on the R&D and production of new small molecule drugs, advanced intermediates and peptide fragments (Zhejiang Hangzhou R&D Center + Jiande GMP Commercialization Base). In terms of peptide APIs, there is a large production capacity of side chain chemically modified peptides and long chain modified peptides with a single batch of 10 kg or more, and the production capacity of peptide APIs has reached tonnage (expected to reach several tonnage by the end of 2025). A quality management system in line with USFDA/EDQM/NMPA has been established. The Lianyungang factory has successively passed the US FDA on-site inspection/flight inspection, South Korea MFDS, Brazil ANVISA and other inspections. The R&D team is led by experts such as the "100 Talents Program" of the Chinese Academy of Sciences, and provides CDMO/CMO services from advanced intermediates and APIs to preparations for innovative pharmaceutical companies around the world. It has R&D centers and production bases in Hangzhou/Lianyungang/Jiande and more than 2,000 employees.

Jiangsu AmbioPharm Biopharmaceutical Co., Ltd. is located at No. 78, Economic and Technological Development Zone Kunlunshan Road, Lianyungang, Jiangsu Province, China.

Main peptides produced: Tirzepatide, Semaglutide, Liraglutide.

Website: https://www.noblepeptide.com